HK Stock Market Move | MIRXES-B(02629) rose by over 35% during trading hours, reaching a new high. The company is a Singapore-based early cancer screening enterprise, and has recently been included in the Hong Kong Stock Connect program.

MIRXES-B (02629) surged more than 35% during trading hours, hitting a high of 59.5 Hong Kong dollars to set a new record high, exceeding the IPO price of 23.3 Hong Kong dollars by over 150%. As of the time of writing, it has increased by 24.43% to 54.75 Hong Kong dollars, with a trading volume of 5.66 billion Hong Kong dollars. On the news front, according to an announcement by the Hang Seng Index Company on August 22, Mirxes has been included in the Hang Seng Composite Index. The relevant changes took effect from September 8, and the company has officially become a constituent stock of the Hong Kong Stock Connect under Shanghai-Hong Kong Stock Connect. Public information shows that Mirxes is a miRNA technology company headquartered in Singapore, dedicated to making disease screening and diagnostic solutions accessible in key Asian markets. As of the latest practicable date, the group has a core product (GASTROClearTM), two other commercialized products (LUNGClearTM and FortitudeTM), and six pre-clinical candidate products. It is reported that the group's core product GASTROClearTM is a blood-based miRNA test kit for gastric cancer screening, composed of 12 miRNA biomarkers. This product was successfully commercialized in Singapore after obtaining a Class C in vitro diagnostic (IVD) certificate from the Singapore Health Sciences Authority (HSA) in May 2019.